Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCapricor Therapeutics Inc

Capricor Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
9.0 USD 0.40 ( 4.65%)
Last update at 2026-11-06T21:01:00Z
VOLUME
4620439
Market Cap
2044.07M

Momentum Score

…

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.30
Low
9.11
High
52 Week Price Range
4.30
Low
40.37
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies for rare muscular and cardiovascular diseases, including Duchenne muscular dystrophy. Long-term growth drivers include clinical trial progress and regulatory outcomes for its lead programs, potential commercialization or partnering, and platform expansion to additional indications. Investors may find exposure to a differentiated regenerative-medicine platform with potential disease-modifying benefits.

Major risks are significant clinical and regulatory uncertainty, limited or no product revenue with likely need for additional financing and dilution, and operational challenges around manufacturing and competition.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.60
Dividend Yield
-
Revenue TTM
11.13M
Revenue Per Share
0.24
Gross Profit TTM
-84.45M
Debt / Equity
0.07
ROE
-46.56%
Net Debt
-266.90M
ROCE
-33.78%
Diluted EPS TTM
-2.26

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -105.04M -40.47M -22.29M -29.02M -20.02M
Net income -105.04M -40.47M -22.29M -29.02M -19.41M
Selling general administrative 22.75M 14.87M 12.81M 10.43M 7.61M
Selling and marketing expenses - - 12795.30M - -
Gross profit - -27.70M -11.27M 2.55M 0.24M
Reconciled depreciation 1.89M 1.43M 0.95M 0.53M 0.25M
Ebit - -42.56M -24.08M -29.70M -20.94M
Ebitda -108.14M -41.14M -23.01M -30.18M -21.31M
Depreciation and amortization - 1.43M 1.07M -0.49M -0.37M
Non operating income net other - - - 0.68M 0.92M
Operating income -108.14M -42.56M -24.08M -29.70M -20.94M
Other operating expenses 108.14M 64.84M 49.26M 32.25M 21.18M
Interest expense 3.05M 0.00M - -1.70M 1.04M
Tax provision 0.00M 0.00M - - -
Net interest income -3.05M 0.00M - - -
Income tax expense - - -0.00M -0.00M -0.61M
Total revenue 0.00M 22.27M 25.18M 2.55M 0.24M
Total operating expenses 108.14M 14.87M 12.81M 32.25M 21.18M
Cost of revenue - 49.97M 36.45M - -
Total other income expense net 3.10M 2.10M 1.79M 0.68M 0.92M
Net income from continuing ops -105.04M -40.47M -29.25M -29.02M -20.02M
Net income applicable to common shares - - - -29.02M -20.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 355.95M 170.48M 58.73M 50.09M 41.33M
Other current assets 4.75M 1.50M 1.00M 0.92M 1.16M
Total liab 50.16M 25.02M 36.13M 38.31M 9.96M
Total stockholder equity 305.79M 145.46M 22.60M 11.79M 31.37M
Other current liab 15.56M 12.01M 6250.24M 0.09M 3.72M
Common stock 0.06M 0.05M 0.03M 0.03M 0.02M
Capital stock 0.06M 0.05M 0.03M 0.03M 0.02M
Retained earnings -304.88M -199.83M -159.37M -137.08M -108.06M
Other liab - - - 12.84M 3.38M
Other assets - - - 0.27M 0.28M
Cash 287.85M 11.29M 14.69M 9.60M 34.89M
Total current liabilities 35.84M 21.03M 31.27M 23.59M 4.13M
Current deferred revenue 12.00M 12.00M 24.27M 17.98M -
Net debt -266.90M -9.84M -9.08M -7.04M -32.01M
Short term debt 6.62M 0.83M 0.75M 0.68M 0.42M
Short long term debt total 20.94M 1.45M 5.61M 2.56M 2.87M
Other stockholder equity 610.33M 344.22M 181.70M 148.74M 139.40M
Property plant equipment - - - 4.59M 4.62M
Total current assets 322.94M 163.39M 50.86M 42.89M 36.44M
Net tangible assets - - - 11.79M 36.74M
Short term investments 30.28M 140.23M 24.79M 31.82M -
Net receivables 0.06M 10.37M 10.37M 0.55M 0.39M
Long term debt - - - 3.38M 3.38M
Inventory - - 0.00M - -
Accounts payable 1.65M 8.18M 6.25M 4.83M 3.12M
Accumulated other comprehensive income 0.28M 1.03M 0.24M 0.11M -
Common stock total equity - - - 0.03M 0.02M
Retained earnings total equity - - - -137.08M -108.06M
Non currrent assets other 14.70M 0.22M 0.27M 0.27M 0.28M
Non current assets total 33.01M 7.10M 7.88M 7.21M 4.89M
Capital lease obligations 14.52M 1.45M 2.24M 2.56M 2.87M
Long term debt total - - - 3.38M 3.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 109.20M -116.18M 16.11M -31.71M -1.20M
Change to liabilities - - - 1.21M 0.99M
Total cashflows from investing activities 97479.28M -116.18M 5.11M -35.07M -1.20M
Total cash from financing activities 248892.30M 152.77M 25.58M 4.87M 20.23M
Change to operating activities - - - 0.25M -0.42M
Net income -105043.95M -40.47M -22.29M -29.02M -20.02M
Change in cash 276560.32M -3.41M 5.09M -25.28M 2.22M
Begin period cash flow 11287.00M 14.69M 9.60M 34.89M 32.67M
End period cash flow 287847.31M 11.29M 14.69M 9.60M 34.89M
Total cash from operating activities -69811.26M -40.00M -25.60M 4.92M -16.81M
Issuance of capital stock 237.03M 152.32M 5.27M 4.80M 20.17M
Depreciation 1889.04M 1.43M 1.07M 0.53M 0.25M
Other cashflows from investing activities -8819.74M -1.54M - -1.36M -
Change to inventory - - - - 391.75M
Change to account receivables 10.31M 0.00M -9.82M -0.00M -391.75M
Sale purchase of stock - - - 4.87M 20.23M
Other cashflows from financing activities 248643.40M 0.45M 0.06M 0.07M 0.05M
Change to netincome - - - 4.49M 2.79M
Capital expenditures 2904.46M 1.54M 2.05M 3.36M 1.20M
Change receivables - - - -0.16M -0.39M
Cash flows other operating - - - 27.86M -0.02M
Cash and cash equivalents changes - - - -25.28M 2.22M
Change in working capital 12.20M -10.78M -11.75M 28.75M 0.18M
Stock based compensation 16967.80M 9.77M 7.39M 4.46M 2.97M
Other non cash items 16363.65M 0.07M -0.02M 0.20M 0.13M
Free cash flow -72715.72M -41.53M -27.64M 1.56M -18.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CAPR
Capricor Therapeutics Inc		 0.40
4.65%		 9.00 - 78.74 124.43 6.47 141.52 -2.73
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

10865 Road to the Cure, San Diego, CA, United States, 92121

858 727 1755

https://www.capricor.com

231

Name Title Year Born
Dr. Frank Isaac Litvack FACC, M.D. Exec. Chairman 1956
Dr. Linda Marbán Ph.D. Co-Founder, Pres, CEO & Director 1963
Mr. Anthony J. Bergmann M.B.A. CFO & Corp. Treasurer 1986
Ms. Karen G. Krasney Exec. VP, Gen. Counsel & Sec. 1953
Dr. Eduardo Marbán Co-Founder & Chairman of Scientific Advisory Board NA
Mr. Xavier Avat Chief Bus. Officer NA
Dr. Deborah D. Ascheim Consultant 1965
Catherine Lee Kelleher Consultant NA
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 1956
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…